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Case Study

Implementation of order sets for opioid alternatives in
community hospital emergency departments
Purpose. The design and implementation of alternatives to opioids (ALTO)
order sets for the treatment of acute pain in a community health system’s
emergency departments are described.

William Armstrong, PharmD, BCPS,
Department of Pharmacy, Parkview
Health, Fort Wayne, IN

Summary. Healthcare institutions nationwide have incorporated policies
and procedures to assist prescribers in the safe and effective management of pain. These adopted approaches may be targeted at mitigating
opioid prescribing as well as promoting the optimization of nonopioid
analgesics. Institutions that enact innovations and track outcomes may
be eligible for reimbursement through the Centers for Medicare and Medicaid Services’ Merit-based Incentive Payment System. Emergency departments may monitor implementation progress and outcomes through
participation in the American College of Emergency Physician’s Emergency Quality Network. Clinical pharmacists were tasked with assisting an
institution’s emergency departments to create and implement two order
sets containing ALTO analgesics and supportive medications for atraumatic headache and general acute pain management. Key steps of order
set implementation included collaborative development with emergency
department providers, implementation with information services, and the
development of provider-focused education by project pharmacists. The
implementation of ALTO order sets has set the foundation for expansion of
pain control protocols and algorithms within our institution. Furthermore,
the approach detailed in this article can be adapted and implemented by
other healthcare systems to help reduce opioid prescribing.

Sarah Meeks, PharmD, BCCCP,
Department of Pharmacy, Parkview
Health, Fort Wayne, IN

Conclusion. The implementation of ALTO order sets within an electronic
health record can encourage decreased prescribing of opioids for the
treatment of acute pain, promote and optimize dosing of nonopioid analgesics, and may augment reimbursement for services in the emergency
department.
Keywords: analgesics; emergency medicine; medication-use technology;
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B

etween 1999 and 2007, US opioid
overdose–related deaths per year
rose from 8,048 to 18,515, with an exponential increase to 47,600 in 2017.1 In
October 2017, the United States declared
the opioid crisis a national public health
emergency.2 Since 2007, overdose deaths
related to use of prescription opioids
have gradually increased, whereas deaths
associated with street drugs like heroin
have escalated rapidly.1 In a survey of
nonprescription opioid abusers, many
patients reported that their first abused
opioid was a prescription drug.3

Address correspondence to Dr. Netley
(jnetley.pharmd@outlook.com).
© American Society of Health-System
Pharmacists 2020. All rights reserved.
For permissions, please e-mail: journals.
permissions@oup.com.
DOI 10.1093/ajhp/zxaa166

1258

 AM J HEALTH-SYST PHARM

|

VOLUME 77

|

NUMBER 15

|

AUGUST 1, 2020

In light of the opioid crisis, it is
especially important for healthcare
providers to be judicious in the administration and prescribing of these medications. Pain is commonly encountered
in the emergency department (ED)
setting, and rapid clinical decision
making is required in order to address
appropriately. To help assist in this
clinical decision making, healthcare institutions nationwide have taken steps
to assist prescribers in the efficient
and appropriate management of pain
through nonopioid modalities by the
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incorporation of alternatives to opioids
(ALTO) protocols, pain management
algorithms, and order sets. These resources may be used by institutions to
facilitate the development of opioidsparing interventions.

Parkview Health is a communitybased health system located in
northeastern Indiana. The health
system is comprised of a level II trauma
center, an urban hospital, and 6 rural
community hospitals. In 2018, approximately 206,000 patient visits occurred
across all EDs within the health system.
The ED provider group is composed of
physicians and physician assistants,
who routinely rotate among hospital locations for staffing. Decentralized clinical pharmacist coverage is provided at
the level II trauma center’s ED during
the evening shift 7 days a week.
Parkview Health participates in
the American College of Emergency
Physician (ACEP) Emergency Quality
Network
(E-QUAL)
program.4
Participation in the E-QUAL program facilitates benchmarking and
reporting to the Centers for Medicare
and Medicaid Services’ Merit-based
Incentive Payment System (MIPS).5
The E-QUAL program offers emergency
medicine–focused initiatives to meet
the MIPS performance requirements
for improvement activities, which mandate that participants actively try to improve the quality and reduce the cost
of care. Demonstrating that efforts are
made to meet improvement activities
requirements helps institutions earn
performance-based adjustments of
Medicare Part B payments. For the 2018
calendar year, Parkview Health elected
to participate in improvement activities
related to the opioid management with
the goal of reducing opioid-associated
harm through safer prescribing and
the implementation of evidencebased interventions. Participation in
the opioid management improvement
activities required that one of the following specific pain indications be
selected for evaluation: low back pain,
atraumatic headache pain, or dental

prototype, promote the advantages of
ALTO order sets vs opioid prescribing,
and encourage provider discussion
and feedback. The objectives for the
presentations were met by delivering a
presentation that briefly described the
national and local impact of the opioid
crisis, visually demonstrated use of
the ALTO order set, and detailed how
the project correlated to institutional
opioid-reduction strategies. After the
presentation, providers were given a
written questionnaire designed to assess overall provider support for the
order set and, more specifically, the analgesics that were initially proposed for
inclusion in the order set project. Space
was available for providers to write in
additional comments and provide suggestions for other nonopioid analgesics
not initially included.
Two major project changes occurred as a result of provider discussion during grand rounds. First, the
discussion led to the creation of 2 separate order sets targeting pain; this was
done to accommodate 2 areas of provider concern. A majority of providers
were concerned that further expansion of the number of analgesics included in the initially proposed order
set would create an overly lengthy
order set that would hinder order selection. Additionally, some providers
were concerned that a single order set
might not be enough. Therefore, they
proposed creation of a second order
set specifically for medications used to
treat atraumatic headache would allow
for headache-specific analgesics to be
included on a second, more concise
order set, which would align with and
promote E-QUAL initiative goals.
The second major change was to
include the order sets as a link on the
ED provider Quicklist, a rapid-ordering
functionality within the Epic EHR
system (Epic Systems Corporation,
Verona, WI), rather than requiring a
search of available order sets within
the order set search bar. Within our
EHR, the ED providers have a Quicklist
screen that encompasses commonly
used medications, laboratory results,
consultations, and radiological tools.

Problem
ED providers were tasked with
implementing opioid optimization
strategies that would meet the improvement activities requirements,
address the opioid crisis by promoting
use of nonopioid modalities, and could
be executed across all EDs within the
health system. Earlier in 2018, the
state’s opioid prescription drug monitoring program (PDMP) was integrated
into the electronic health record (EHR)
to allow providers to consult the database prior to prescribing opioid therapies. Incorporating the PDMP into the
EHR earned points for improvement
activities in the E-QUAL program; however, additional points were required
in order to fully meet the initiative.
ED providers requested the development of decision support tools and
treatment protocols to aid in analgesic
prescribing.
As a result, ED physicians, in collaboration with the project pharmacists,
decided to design ALTO order sets that
could be integrated into the EHR. Two
objectives were deemed necessary by
initiative leaders to help guide ALTO
order set creation to maximize benefits for patients and the health system:
(1) the order sets needed to promote
ACEP’s policy statement that acutely
painful conditions in the emergency
department should optimally begin
with a nonopioid agent,6 and (2) an
order set was needed to meet the criteria for promoting safe and effective
nonopioid analgesia for atraumatic
headache. Additionally, providers requested that order sets be user-friendly
and that selection of medications for inclusion in order sets be evidence based.

Analysis and resolution
Prototype reveal for provider
feedback. Project pharmacists delivered a presentation during monthly
ED grand rounds. Objectives of the
presentation were to reveal the order set
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Background

pain. Atraumatic headache pain was
selected by Parkview Health as the
measure to be targeted for improvement and assessment.
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implementation of the ALTO order sets.
Survey results showing provider preferences regarding a list of medications
originally proposed for inclusion in
order sets, as well as write-in suggestions, are presented in Table 1.
Order set analgesic selection.
Of the 12 medications originally proposed for order set inclusion, only 2
garnered less than 50% provider support. Despite intravenous (i.v.) lidocaine having less than 50% provider
support, it was selected for order set
inclusion; but was deemed necessary
to build a distinct analgesic i.v. lidocaine order in addition to the existing
antiarrhythmic order to reduce dosing

Table 1. Results of Survey of Provider Preferences for Medications to be
Included in ALTO Order Set
No. (%) Supporting Inclusion
(n = 32)

Medication (Route)
Initially proposed for inclusion
Acetaminophen (oral)

29 (91)

Ibuprofen (oral)

29 (91)

Ketorolac (i.v.)

29 (91)

Lidocaine (transdermal)

26 (81)

Metoclopramide (i.v.)

26 (81)

Dicyclomine (oral)

25 (78)

Orphenadrine (i.v.)

24 (75)

Cyclobenzaprine (oral)

23 (72)

Rizatriptan (oral)

17 (53)

Sumatriptan (subcutaneous)

17 (53)

Lidocaine (i.v.)

14 (44)

Gabapentin (oral)

6 (19)

Proposed by write-in request
Orphenadrine (i.m.)

13 (41)

Dicyclomine (i.m.)

11 (34)

Acetaminophen (i.v.)

10 (31)

Ketorolac (i.m.)

6 (19)

Haloperidol (i.v.)

5 (16)

Prochlorperazine (i.m.)

5 (16)

Orphenadrine (oral)

2 (6)

Magnesium (i.v.)

1 (3)

Dihydroergotamine (i.v.)

1 (3)

Abbreviations: ALTO, alternatives to opioids; i.m., intramuscular; i.v., intravenous.
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and administration errors. Specifically,
the i.v. lidocaine for analgesia order
included a built-in maximum dose,
slower administration rate, and required cardiac monitoring. Due to
lack of support, gabapentin was removed from the order set. The lack of
support for gabapentin was based on
skepticism of its use as an acute analgesic and concern regarding potential
adverse effects if the dose were not
tapered appropriately. Additionally,
our institution routinely serves patients
from Ohio, which recently categorized
gabapentin as a schedule V controlled
substance. Rizatriptan and sumatriptan
had a lower provider preference rating,
but it was theorized that the approval
rating may have reflected the original
proposal for one order set and that providers might not have considered that
these medications would be limited to
the atraumatic headache order set.
With consideration of the 9 provider
write-in recommendations, 6 additional agents were added to the order
sets. Some analgesics with alternate
routes of administration were requested
by multiple providers for addition to the
order sets, such as intramuscular and
oral orphenadrine and intramuscular
dicyclomine. Other agents did not have
multiple write-in requests for addition
to the order sets but were ultimately
included, such as i.v. magnesium and
i.v. dihydroergotamine. To ensure the
atraumatic headache order set had a
sufficient breadth of agents available
for selection, these medications were
reviewed and added despite less than
50% provider support. Intravenous
acetaminophen was requested by multiple providers, but due to institutional
cost-based formulary restrictions, the
medication was not added to the order
sets. Due to a concurrent evaluation
of ketamine order sets for analgesia
in the ED, ketamine was not added to
the ALTO order sets to prevent confounding of project results.
After analyzing provider responses
regarding analgesic selection, project pharmacists began the process of
evaluating route, dose, and frequency
for the creation of the 2 order sets. While
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The Quicklist facilitates expedited ordering from a single screen as opposed
to searching for individual orders.
Having the orders sets included as part
of the Quicklist was significant as it allowed providers to have easier access
to the order sets, and its appearance
on the medications tab served as a reminder for provider usage.
Proposed changes to the order
set prototype primarily were derived from feedback on the questionnaire distributed to 46 ED providers.
The questionnaire response rate was
69.6% (32 of 46 providers). Responses
to the questionnaire showed that 29
of 32 providers (90.6%) supported
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Prior to order set creation, some
medications that were incorporated
into the order sets were available on
the ED Quicklist. To encourage order
set usage and congregate similar medications, several medications were
removed from the ED Quicklist and
transitioned to the order sets. The
medications that were removed were
nonopioid analgesics not used for alternative therapies (eg, dicyclomine).
Medications that have alternative therapies, such as fever reduction, were still
included in the order sets and included
on the Quicklist for provider accessibility (eg, acetaminophen).
Project pharmacists collaborated
with the IS team to set the default
dose, route, and frequency for each
medication. Pharmacists made additional recommendations regarding
prespecified buttons available for
each medication when the full order is
opened. When deemed necessary, additional order and administration comments were drafted by the pharmacists
and incorporated into the order. For example, the i.v. lidocaine included a note
that cardiac monitoring was required
during the administration period.
Additionally, each medication’s priority
status, as well as the need for pharmacist verification, was evaluated by the
pharmacists. Medications deemed appropriate for autoverification did not
need a change in dispensing status
(ie, emergent vs routine) because
they would be readily available for administration after the order is placed.
For medications deemed to require
pharmacist verification, the priority
status was changed to “stat” so that the
medications would appear at the top of
the pharmacist verification queue to reduce time to medication availability.
Provider education. Education
was developed by project pharmacists and targeted to ED providers.
The questionnaire distributed to providers during the grand rounds presentation included an assessment of
preference of education format and
included the options of an emailed
handout, a slideshow presentation, or
a live in-service. An emailed handout

with first-line options as well as medications with off-label pain indications.
Low-dose haloperidol was added to the
order set for consideration in the adjuvant treatment of abdominal pain and
gastroparesis refractory to other pain
control interventions.8 Intravenous
lidocaine was added because recent literature supports its use for the management of pain associated with renal colic.9
Several other novel pain control approaches, including ultrasound-guided
nerve blocks and inhaled nitrous oxide,
were discussed during the inaugural
meeting; however, these interventions
were not included in the final order sets
due to cost considerations and complex
administration requirements.
Lastly, per provider request, addi
tional medications were selected for
their supportive care benefits when
used in conjunction with medications
on the order set (eg, the treatment of
nausea for patients with migraine).
Diphenhydramine monotherapy is
not commonly used for the treatment
of migraine headaches but can be administered with metoclopramide as
adjuvant therapy. Additionally, diphenhydramine may reduce the occurrence of undesirable adverse effects
associated with metoclopramide (eg,
akathisia). Initially, potential inclusion
of ondansetron in the order sets was
not discussed, as only medications for
which there was published data to support use as adjuvant therapies were
discussed. Several weeks later, to aid
in ordering and reduce provider ordering fatigue, ondansetron was added
to the atraumatic headache order set,
as it was felt the drug would be ordered
at the same time as analgesia for the
acute management of migraines. The
completed order sets are detailed in
Tables 2 and 3.
Order set implementation.
Within our institution, the information services (IS) department has a division dedicated to in-house builds and
support for the Epic EHR. The pharmacy and ED have dedicated members within the EHR service center who
were able to incorporate the order sets
into the ED provider Quicklist.
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many agents selected for the order sets
can be administered at different doses
and frequencies, the project pharmacists reviewed literature and other institutions’ nonopioid analgesic programs
to optimize the default dose of each
medication specified in the order sets. If
providers wanted to change the dose or
frequency, they had the option to open
the full order and make adjustments via
other preselected dose and frequency
buttons. For example, the 15-mg dose
of ketorolac was selected as the default
dose, as recent literature from Motov
et al7 indicated that doses greater than
10 mg were not more effective in pain
reduction. As 15-mg ketorolac dose increments are commonly used within
our institution, 15 mg was selected as
the default option. However, providers
have the option to open the full order,
where prespecified buttons for 10-,
15-, and 30-mg doses are available.
Additionally, some medications on the
order sets can be given both intravenously and intramuscularly. Both safety
of administration and provider preference of administration route were assessed when selecting a default route.
Providers could alter the default parenteral route of administration after
selecting the medication on the order
sets. Since orphenadrine is supplied in
both oral and injectable formulations, a
separate entry was created for the oral
formulation to prevent errors in dosing,
as the i.v.-to-oral conversion ratio is
not 1:1.
Although orphenadrine is not referenced frequently in various pain
guidelines, provider preference for its inclusion in an order set was strong within
our institution. Orphenadrine, like other
muscle relaxants, can be used to treat
musculoskeletal pain as monotherapy
or used in combination with initial pain
therapies such as acetaminophen and
ibuprofen. Within the order sets, providers can select multiple agents at once
to create a multimodal approach to the
treatment of acute pain if it is deemed
that monotherapy is not clinically appropriate. Additionally, the order sets included several medications as adjuvant
therapy for pain that could be combined
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Table 2. Medications in ALTO Order Set for Generalized Pain, With Default Dose, Route, and Frequency
Medication

Formulation

Dose

Route

Frequency

Tablet

1,000 mg

Oral

Every 6 hours

Tablet

400 mg

Oral

Every 6 hours

Ketorolac

Injection

15 mg

i.v.

Every 6 hours

Dicyclomine

Capsule

20 mg

Oral

Every 6 hours

Dicyclomine

Injection

20 mg

i.m.

Every 6 hours

Orphenadrine

Tablet

100 mg

Oral

Every 12 hours

Orphenadrine

Injection

60 mg

i.v.

Once

Tablet

10 mg

Oral

Every 8 hours

Lidocaine

Cyclobenzaprine

Infusion

1.5 mg/kg

i.v.

Once

Lidocaine

Patch

4% patch

Transdermal

Every 24 hours

Injection

2 mg

i.v.

Once

Haloperidol

Abbreviations: ALTO, alternatives to opioids; i.m., intramuscular; i.v., intravenous.

Table 3. Medications in ALTO Order Set for Atraumatic Headache, With Default Dose, Route, and Frequency
Medication

Formulation

Dose

Route

Frequency

Acetaminophen

Tablet

1,000 mg

Oral

Every 6 hours

Ibuprofen

Tablet

400 mg

Oral

Every 6 hours

Ketorolac

Injection

15 mg

i.v.

Once

Metoclopramide

Injection

10 mg

i.v.

Once

Diphenhydramine

Injection

25 mg

i.v.

Once

Prochlorperazine

Injection

10 mg

i.m.

Once

Dexamethasone

Injection

8 mg

i.v.

Once

Magnesium

Infusion

1g

i.v.

Once

Rizatriptan

Tablet

10 mg

Oral

Once, may repeata

Sumatriptan

Injection

6 mg

Subcutaneous

Once

Dihydroergotamine

Injection

1 mg

i.v.

Once, may repeatb

Ondansetron

ODT

4 mg

Oral

Once

Ondansetron

Injection

4 mg

i.v.

Once

Abbreviations: ALTO, alternatives to opioids; i.m., intramuscular; i.v., intravenous; ODT, orally disintegrating tablet.
a
Repeat dose may be given once after 2 hours if significant relief not attained (maximum dose of 20 mg in 24 hours).
b
Repeat dose may be given once after one hour if significant relief not attained (maximum dose of 2 mg in 24 hours).

was the preferred route of education.
The objective of the education was to
provide an overview of order set function, information about medications
on the order sets, and possible benefits of order set utilization. Overview
of the order sets included their location within the Quicklist and functionality of ordering within the order set.
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on each order set, default settings and
available alternative prespecified options, discussion of possible adverse effects and monitoring needs, and clinical
pearls for provider consideration. The
review of the benefits of order set utilization primarily focused on reduction
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of opioid prescribing and the functionality of selecting multiple medications
in the order set to create a multimodal
approach for pain management.
Provider education was conducted
2 weeks prior to the implementation of
the order sets. A pharmacist presence
in the ED during the implementation
period (both clinical pharmacists and
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Discussion
From the inaugural meeting to completed EHR implementation, the project took place over a 6-month period.
Order set usage is trackable within the
data analytic center within the EHR.
This allows project pharmacists to have
the opportunity to complete drug use
evaluations for order set analgesics
and opioids prescribed in the ED.
Areas for possible evaluation include
comparison of morphine milligram
equivalents administered to patients
who receive medications from an ALTO
order set and those who did not, comparisons of pain and satisfaction scores,
and rates of discharge prescriptions
for opioid agents. Participation in the
E-QUAL program to improve MIPS reimbursement does not require submission of data to demonstrate that system
improvement processes correlate with
a reduction of opioid prescribing and
adverse effects. Implementation of
the order sets meets specific parts of
the criteria but not all necessary criteria. Thus, together with fulfillment of
other criteria by the health system and
medical director, the order set project
resulted in an increase in MIPS reimbursement for the next calendar year.
At our institution, as providers become more accustomed to ordering
from the ALTO order sets and gain
confidence treating pain without the
need for opioids, the implementation
of further transitional steps can be facilitated. The philosophy of the project was to implement incremental
projects one at a time rather than creating large-scale changes in order to
maintain provider buy-in and not disrupt other aspects of the current patient care model. One opportunity for
further enhancement of this project

and to provide more comprehensive
analgesic options. Additionally, as provider preferences change and new information on nonopioid analgesic
options emerges, the order sets can be
expanded to include therapies not already included. Previously discussed
options may also be reviewed, with reconsideration for order set inclusion at
a future time. Intravenous acetaminophen was not included in the order sets
due to health-system restrictions on use
of the medication due to its higher cost
relative to alternative formulations. Due
to the high level of support for inclusion
of i.v. acetaminophen in the order set initiative expressed during grand rounds,
future evaluations could lead to expansion of the health system restrictions to
include a 1-time dose in the ED; however, this would likely require additional
criteria prior to use, as it would not be a
preferred first-line formulary option for
all pain types.

development could be the removal of
opioid medications from the Quicklist
and requiring providers to access them
via a medication search. The objective
of this would be to limit the ease of
ordering opioids and encourage further reduction in overall opioid prescribing. During our implementation,
opioids were not removed from the
Quicklist due to provider pushback,
including concerns about increased
time to therapy for patients for whom
prescribing an opioid would be appropriate and about provider dissatisfaction due to loss of convenience.
When evaluating which type of
intervention to make within our institution, we identified institutions that had
implemented treatment algorithms or
incorporated additional stepwise guidance within order sets to standardize
care for specific pain indications. Such
interventions were not made within our
institution; instead, the implemented
order sets allowed providers to select
therapy deemed clinically appropriate
outside of an algorithm. The education
that was provided as part of the order set
implementation did not direct providers
to select first-, second-, or third-line
treatment options but rather provided
details of what type of pain or combination of therapy may be appropriate for
different types of pain within the clinical
pearls section. Depending on data compiled during the initial review of order
set implementation, if order set education and availability alone do not result
in a trend towards opioid reduction and
increased opioid alternative usage, then
further prescribing recommendations
and algorithm guidance can be built
within the order sets.
As previously mentioned, ketamine
was not included in the initial ALTO
order sets due to concurrent project
evaluation. While ketamine usage was
not evaluated as part of the project described here, the concurrent project supported a similar goal of opioid reduction
through its focus on ketamine as an analgesic. Following completion of the concurrent project evaluation, there may be
a future opportunity to include ketamine
in the ALTO order sets for convenience
AM J HEALTH-SYST PHARM
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Conclusion
The implementation of ALTO order
sets within our institution’s EHR helped
to secure increased MIPS reimbursement relating to participation in ACEP’s
E-QUAL initiative. Additional objec
tives of order set implementation are
to decrease prescribing of opioids for
acute pain treatment, promote and optimize dosing of nonopioid analgesics,
and further increase pharmacists’ ED
involvement.
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